#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	7874	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2513	922.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1614	1614	C	1074	C	969	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12268	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4270	859.2	0	.	n	.	0	T695C	SNP	695	695	T	1218	1218	C	891	C,T,A	807,4,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12268	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4270	859.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1860	1860	A	1072	A,T	981,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12268	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4270	859.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2494	2494	C	1103	C,T,A	1005,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12268	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4270	859.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3120	3120	T	1031	T,C	937,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	12268	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4270	859.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2568	2568	A	1121	A,G,C	1030,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1198	folP	852	852	100.0	folP.l15.c4.ctg.1	1989	179.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1209	1211	AGC	252;252;250	A;G;C	221;232;218	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2360	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3756	187.8	1	SNP	p	S91F	0	.	.	271	273	TCC	787	789	TCC	214;215;215	T;C;C,T,A	198;203;201,1,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2360	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3756	187.8	1	SNP	p	D95G	0	.	.	283	285	GAC	799	801	GAC	216;216;217	G;A;C	202;199;202	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2360	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3756	187.8	1	SNP	p	D95N	0	.	.	283	285	GAC	799	801	GAC	216;216;217	G;A;C	202;199;202	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1166	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1870	186.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	705	707	ACC	305;305;306	A,G;C;C	271,1;274;274	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1166	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1870	186.8	0	.	p	.	0	R44H	NONSYN	130	132	CGC	720	722	CAC	308;312;313	C;A,G;C	279;282,1;284	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1166	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1870	186.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	903	905	CAC	315;316;316	C,T;A;C	288,1;297;297	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1166	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1870	186.8	1	SNP	p	G45D	0	.	.	133	135	GGC	723	725	GGC	314;314;315	G;G;C,G	285;284;283,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	814	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1636	149.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3547	238.5	1	SNP	p	D86N	0	.	.	256	258	GAC	890	892	GAC	324;323;323	G;A;C	287;283;293	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3547	238.5	1	SNP	p	S87R	0	.	.	259	261	AGT	893	895	AGT	323;323;324	A;G;T	285;295;295	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3547	238.5	1	SNP	p	S87W	0	.	.	259	261	AGT	893	895	AGT	323;323;324	A;G;T	285;295;295	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3547	238.5	1	SNP	p	S87I	0	.	.	259	261	AGT	893	895	AGT	323;323;324	A;G;T	285;295;295	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2824	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3547	238.5	1	SNP	p	S88P	0	.	.	262	264	TCC	896	898	TCC	324;325;326	T,A;C;C	289,1;297;301	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2226	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3331	200.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1854	1856	GGC	282;281;282	G;G,C;C	259;252,1;257	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1471	1473	GCA	316;316;316	G,A;C,A;A	283,1;285,1;287	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1474	1476	ATC	318;318;316	A;T,C;C	282;282,1;280	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1486	1488	GTG	312;310;309	G,A;T;G,A	282,1;274;274,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1486	1488	GTG	312;310;309	G,A;T;G,A	282,1;274;274,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1990	1992	ACC	216;219;219	A;C;C	185;194;195	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2044	2046	GCG	200;201;203	G;C,G,A;G,A	183;168,2,1;172,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2044	2046	GCG	200;201;203	G;C,G,A;G,A	183;168,2,1;172,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2167	2169	GGC	227;226;225	G,T;G;C,T	203,1;205;202,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2176	2178	GGC	229;229;228	G,T,C;G;C,G,A	207,1,1;205;205,1,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2070	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2871	215.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2194	2196	CCG	224;224;222	C,G;C;G	187,2;192;188	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2574	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3635	212.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1318	porA	1146	1146	99.83	porA.l6.c30.ctg.1	2300	171.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	821	821	C	212	C	192	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	0	.	p	.	0	E48K	NONSYN	142	144	GAA	399	401	AAA	352;352;353	A,G;A;A	321,2;318;319	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	516	518	GCT	328;328;328	G,A,T;C;T	293,2,1;300;303	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	822	824	AGC	323;322;324	A,C;G,A;C,A	297,1;292,3;297,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	888	888	T	311	T	281	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	1	SNP	p	G120K	0	.	.	358	360	GGT	615	617	GGT	325;325;326	G,T;G,A;T,G,C	292,1;283,1;282,2,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	1	SNP	p	A121N	0	.	.	361	363	GCC	618	620	GCC	325;324;324	G;C,A;C	287;292,1;289	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1670	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1657	280.8	1	SNP	p	A121D	0	.	.	361	363	GCC	618	620	GCC	325;324;324	G;C,A;C	287;292,1;289	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5484	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	5321	308.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2280	2282	AAT	346;344;343	A,C,G;A;T	315,3,1;313;309	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	906	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1527	178.0	1	SNP	p	V57M	1	.	.	169	171	ATG	785	787	ATG	339;338;340	A,C;T;G	308,1;312;307	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
